Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Enalapril Maleate). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Minipril এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Maximum daily dose: 40 mg. Food does not affect the absorption of Enalapril. Essential and renovascular hypertension: Treatment is usually started with 5 mg once a day. If the patient is also taking a diuretic, the recommended starting dose of Enalapril is 2.5 mg. The dose should then be titrated to achieve optimum blood pressure control. The usual maintenance dose is 10 to 20 mg given once daily. In severe hypertension, the dose may be increased step by step to a maximum of 40 mg once daily. Doses of other antihypertensive drugs taken alongside Enalapril may need adjustment. When Enalapril is used to replace a beta blocking drug, the beta blocker should not be stopped suddenly; instead, its dose should be tapered down after Enalapril therapy begins. With concomitant diuretic therapy: The recommended starting dose of Enalapril is 2.5 mg. Symptomatic hypotension can occur after the first dose of Enalapril, and this is more likely when Enalapril is added to existing diuretic treatment. Caution is advised, as these patients may already be depleted of volume or salt. Where possible, diuretic treatment should be stopped for 2 to 3 days before starting Enalapril. Enalapril also helps limit thiazide induced low potassium and raised uric acid levels. Use in the elderly, over 65 years: The starting dose should be 2.5 mg. Enalapril is effective for treating hypertension in elderly patients, and some older patients may respond more strongly to it than younger patients do. The dose should be titrated according to the patient's need for blood pressure control. Heart failure: Enalapril can be used alongside non potassium sparing diuretics and/or digitalis. It should be introduced only after the patient has been stabilised on diuretic therapy, and treatment should begin under close medical supervision, with hospital supervision for severe heart failure. The recommended starting dose is 2.5 mg once daily. The dose should then be increased gradually, as tolerated, up to the recommended maintenance dose of 10 to 20 mg, given as a single dose or split into two daily doses. This dosing schedule has been shown to improve survival. To reduce the risk of symptomatic hypotension, patients who have been on high dose diuretics should have that dose reduced before starting Enalapril. If hypotension appears after the first dose, this does not rule out careful dose titration afterward, once the hypotension has been properly treated. Use in impaired renal function: Enalapril is excreted by the kidneys, so it should be used with caution in patients with renal impairment. The recommended starting dose is 2.5 mg. The dose should be titrated according to response and kept as low as possible while still maintaining adequate control of blood pressure or heart failure. Enalapril can be removed by dialysis. Dialysis patients may be given the usual dose of Enalaprilon dialysis days. On days when the patient is not undergoing dialysis, the dose should be adjusted according to blood pressure response. Children: The use of Enalapril in children has not been studied.
পার্শ্বপ্রতিক্রিয়া
Severe drops in blood pressure and kidney failure have occurred in people taking Anapril, and these tend to appear in certain specific groups of patients. Other side effects include dizziness, headache, tiredness, weakness, a drop in blood pressure on standing up, fainting, nausea, diarrhoea, muscle cramps, rash, and cough. Less often, problems with kidney function, kidney failure, and reduced urine output have been reported. Less common side effects include: heart attack, chest pain, palpitations, irregular heartbeat, angina, pancreatitis, hepatitis (affecting the liver cells or bile flow), jaundice, abdominal pain, vomiting, indigestion, constipation, loss of appetite, mouth inflammation, depression, confusion, drowsiness, insomnia, nervousness, tingling sensations, dizziness/vertigo, wheezing, asthma, breathlessness, runny nose, sore throat and hoarseness, sweating, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, itching, hives, hair loss, impotence, flushing, altered taste, ringing in the ears, tongue inflammation, blurred vision, and others. Swelling beneath the skin (angioedema) affecting the face, limbs, lips, tongue, throat, and/or voice box has rarely been reported.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Pretreatment assessment of renal function is recommended before starting therapy, and periodically during treatment where appropriate. Symptomatic hypotension has rarely been seen in uncomplicated hypertensive patients. It has been reported mainly in patients with severe heart failure who have been volume depleted by diuretic therapy. Starting treatment with a small dose (2.5 mg Anapril) may lessen the duration of any hypotensive effect. The same approach of starting with a small dose may also be appropriate for patients with ischaemic heart disease or cerebrovascular disease, in whom a severe drop in blood pressure could lead to a heart attack or stroke. Severe hypotension has been reported mainly in patients with severe heart failure, with or without associated renal insufficiency. This is most likely in patients on high doses of loop diuretics, or those with low blood sodium or functional renal impairment. If hypotension occurs after the first dose, it does not rule out careful dose titration with the drug once the low blood pressure has been effectively managed. Impaired renal function: Anapril should be used with caution in patients with renal insufficiency, as they may need reduced or less frequent doses. As with all antihypertensive medicines, renal function should be checked in patients with hypertension or congestive heart failure before starting treatment. Angioneurotic oedema has been reported with ACE inhibitors, including Anapril. If this occurs, Anapril should be stopped immediately, and the patient should be monitored appropriately until the symptoms have fully resolved before being discharged. Haemodialysis patients: A high rate of anaphylactoid reactions has been reported in patients dialysed with high flux membranes (such as AN 69) who were also being treated with an ACE inhibitor. Anapril should therefore be avoided in these patients. Cough: Cough has been reported with ACE inhibitors. It is typically dry, persistent, and resolves once treatment is stopped. Surgery and anaesthesia: In patients undergoing major surgery or anaesthesia with agents that lower blood pressure, Anapril blocks the formation of angiotensin II that occurs as a compensatory response to renin release. This may lead to hypotension, which can be corrected with volume expansion. Anapril should not be used in patients with aortic stenosis or outflow obstruction.
নিষেধাজ্ঞা
Contraindicated in patients hypersensitive to the product or its components, and in those with a history of angioneurotic oedema linked to previous ACE inhibitor treatment.